NS Pharma, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$3.1M
Doctors Paid
601
Transactions
2,084
2024 Total
$753,101
Payment Breakdown by Category
Research$2.7M (86.2%)
Consulting$194,443 (6.3%)
Food & Beverage$47,359 (1.5%)
Travel$42,308 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.7M | 617 | 86.2% |
| Consulting Fee | $194,443 | 56 | 6.3% |
| Honoraria | $124,408 | 137 | 4.0% |
| Food and Beverage | $47,359 | 1,188 | 1.5% |
| Travel and Lodging | $42,308 | 76 | 1.4% |
| Grant | $19,000 | 10 | 0.6% |
Payments by Type
Research
$2.7M
617 transactions
General
$427,517
1,467 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| NS-065/NCNP-01-202 - A Phase II, Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys with Duchenne Muscular Dystrophy (DMD) | $903,953 | 0 | 86 |
| A Phase 2 Open-label Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys with Duchenne Muscular Dystrophy (DMD) Compared to Natural History Controls | $344,980 | 0 | 18 |
| Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis | $262,154 | 2 | 19 |
| NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD) | $222,038 | 0 | 25 |
| Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502) | $185,869 | 0 | 103 |
| A Phase 2 Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NS-089/NCNP-02 in Boys With Duchenne Muscular Dystrophy (DMD) | $140,551 | 0 | 21 |
| A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With Duchenne Muscular Dystrophy (DMD) | $121,204 | 0 | 29 |
| A Phase 2 Open-label Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With Duchenne Muscular Dystrophy (DMD) Compared to Natural History Controls | $103,048 | 0 | 14 |
| NS-050/NCNP-03 in Boys With DMD (Meteor50) | $96,172 | 0 | 7 |
| A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally AdministeredNS-018in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF | $62,467 | 0 | 70 |
| A Phase 3, Multi-center, Open-label Extension Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With Duchenne Muscular Dystrophy (DMD) | $55,396 | 0 | 8 |
| Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis | $47,721 | 0 | 96 |
| Phase 4, open-label, single-arm clinical trial assessing the long-term safety and efficacy of Viltepso (viltolarsen) in boys with Duchenne muscular dystrophy (DMD) who completed a prior trial | $32,464 | 0 | 28 |
| Randomized, Controlled Clinical Trial (Phase 2B) Of Ns-018 Versus Best Available Therapy In Subjects With Primary Or Secondary Myelofibrosis With Severe Thrombocytopenia | $32,204 | 0 | 80 |
| Viltolarsen (NS-065/NCNP-01), Ilginatinib(NS-018), Exon 44 skipping DMD therapeutic(NS-089/NCNP-02) | $24,253 | 0 | 2 |
| A Phase 1/2, Open-label, Dose-escalation, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered NS-018 in Patients with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis | $13,822 | 0 | 7 |
| A Phase II, Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD) | $10,064 | 0 | 2 |
| A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys with Duchenne Muscular Dystrophy (DMD) | $5,000 | 0 | 2 |
Payments by Medical Specialty
Top Paid Doctors — Page 8
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Jessica Beardsley | Pediatric Rehabilitation Medicine | Houston, TX | $109.99 | $0 |
| Roberto Lopez-Alberola | Neurology with Special Qualifications in Child Neurology | Miami, FL | $109.82 | $0 |
| Payam Soltanzadeh, Md, MD | Neuromuscular Medicine | Los Angeles, CA | $109.65 | $0 |
| Jose Quintana | Student in an Organized Health Care Education/Training Program | San Juan, PR | $107.95 | $0 |
| Joaquin Wong, M.d, M.D | Pediatrics | New Orleans, LA | $107.17 | $0 |
| Dr. Charles Castro Soto, Md, MD | Pediatrics | Bayamon, PR | $105.64 | $0 |
| Zurisadai Gonzalez Castillo, Md, MD | Neurodevelopmental Disabilities | Dallas, TX | $105.27 | $0 |
| Yong Park, Md, MD | Neurology with Special Qualifications in Child Neurology | Augusta, GA | $104.88 | $0 |
| Giana Nieves | Student in an Organized Health Care Education/Training Program | Ponce, PR | $104.15 | $0 |
| Marisa Mcghee, M.d, M.D | Student in an Organized Health Care Education/Training Program | Winston Salem, NC | $103.97 | $0 |
| Michael Cartwright, Md, MD | Neurology | Winston Salem, NC | $103.97 | $0 |
| Carmen Kiper, Md, MD | Pediatric Cardiology | Charlotte, NC | $103.97 | $0 |
| James Meiling, Do, DO | Neuromuscular Medicine | Rochester, MN | $103.97 | $0 |
| Dr. Danielle Weiss, Md, MD | Epilepsy | Augusta, GA | $102.94 | $0 |
| Wendy Nagle, Np, Cns, NP, CNS | Family | Madera, CA | $101.97 | $0 |
| Katheryn Gambetta, Md, MD | Pediatric Cardiology | Chicago, IL | $100.61 | $0 |
| Dr. Peter Morelli, M.d, M.D | Pediatric Cardiology | Stony Brook, NY | $100.01 | $0 |
| Simona Treidler, M.d, M.D | Internal Medicine | Stony Brook, NY | $100.01 | $0 |
| Dr. Shaguna Mathur, M.d, M.D | Neurology | Omaha, NE | $99.41 | $0 |
| Dr. David Michelson, M.d, M.D | Neurology with Special Qualifications in Child Neurology | West Covina, CA | $97.53 | $0 |
| Sayed Naqvi, M.d, M.D | Neurology with Special Qualifications in Child Neurology | Miami, FL | $97.51 | $0 |
| Maria Weimer, Md, MD | Neurology with Special Qualifications in Child Neurology | New Orleans, LA | $92.65 | $0 |
| Dr. Ariella Cohen, Md, MD | Pediatrics | Philadelphia, PA | $92.51 | $0 |
| Clovalyn Jeffrey-Mcgann, Np, NP | Family | Augusta, GA | $90.98 | $0 |
| Susan Matesanz, Md, MD | Neurology with Special Qualifications in Child Neurology | Philadelphia, PA | $90.50 | $0 |
Ad
Top Products
- VILTEPSO $2.1M
- Viltepso $36,332
Associated Products (3)
- VILTEPSO $2.1M
- Viltepso $36,332
- Viltolarsen (NS-065/NCNP-01) $34,581
Payment Categories
- Food & Beverage $47,359
- Consulting $194,443
- Travel & Lodging $42,308
- Research $2.7M
About NS Pharma, Inc.
NS Pharma, Inc. has made $3.1M in payments to 601 healthcare providers, recorded across 2,084 transactions in the CMS Open Payments database. In 2024, the company paid $753,101. The top product by payment volume is VILTEPSO ($2.1M).
Payments were distributed across 60 medical specialties. The top specialty by payment amount is Specialist ($74,609 to 11 doctors).
Payment categories include: Food & Beverage ($47,359), Consulting ($194,443), Research ($2.7M), Travel & Lodging ($42,308).
NS Pharma, Inc. is associated with 3 products in the CMS Open Payments database.